GenMark Diagnostics CEO Hany Massarany Sells 2,700 Shares (GNMK)
GenMark Diagnostics (NASDAQ:GNMK) CEO Hany Massarany unloaded 2,700 shares of the stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $10.67, for a total transaction of $28,809.00. Following the completion of the transaction, the chief executive officer now directly owns 188,708 shares in the company, valued at approximately $2,013,514. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Shares of GenMark Diagnostics (NASDAQ:GNMK) traded up 2.85% on Thursday, hitting $10.81. 224,311 shares of the company’s stock traded hands. GenMark Diagnostics has a one year low of $8.48 and a one year high of $15.16. The stock has a 50-day moving average of $9.51 and a 200-day moving average of $11.38. The company’s market cap is $449.8 million.
GenMark Diagnostics (NASDAQ:GNMK) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.21) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.25) by $0.04. The company had revenue of $7.91 million for the quarter, compared to the consensus estimate of $6.40 million. During the same quarter in the prior year, the company posted ($0.13) earnings per share. The company’s quarterly revenue was down 28.7% on a year-over-year basis. Analysts expect that GenMark Diagnostics will post $-1.15 EPS for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at Raymond James reiterated an “outperform” rating on shares of GenMark Diagnostics in a research note on Wednesday, May 7th. They now have a $11.00 price target on the stock, down previously from $14.00. Separately, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of GenMark Diagnostics in a research note on Wednesday, May 7th. They now have a $16.00 price target on the stock, down previously from $17.00. Finally, analysts at Cowen and Company reiterated an “outperform” rating on shares of GenMark Diagnostics in a research note on Wednesday, May 7th. They now have a $15.00 price target on the stock, down previously from $16.00. Five equities research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and a consensus price target of $15.00.
GenMark Diagnostics, Inc (NASDAQ:GNMK) is a molecular diagnostics company focused on developing and commercializing its eSensor detection technology.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.